This activity is provided by the University of Kentucky College of Medicine. Paradigm Medical Communications, LLC is the educational partner.
This activity is supported by an unrestricted educational grant from Novartis Pharmaceuticals Corporation.
To receive a CME certificate of participation, please:
Click the "Start Activity" button to go to the Paradigm Medical Communications website, where you will complete the pre-test and view the online activity in its entirety.
After viewing the activity, click "Click Here to Get Credit".
If you are not signed into CECentral.com, you will need to either sign in or create a new free account.
Complete and submit the post-test and evaluation. You must answer 70% of the post-test questions correctly to earn credit. You will have unlimited opportunities to successfully complete the post-test.
Your certificate will display; you can print it or view it later by clicking "Transcript" in the blue bar at the top of the page.
Your certificate will be stored in your transcript on the CE Central/University of Kentucky website and will not be available in your myCME CME History.
There is no fee required for participation in this activity.
If you need assistance obtaining your certificate, please call (859) 257-5320, Monday–Friday, from 8:30 AM–4:30 PM ET.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
New treatments can dramatically improve the quality of life for psoriasis patients by improving many of the serious sequelae currently endured by many patients. This activity will provide healthcare providers with updated information on diagnosis, treatment options, and research protocols for moderate and severe plaque psoriasis. Specific topics include the pathophysiology of inflammatory pathways that drive the pathogenesis of plaque psoriasis; characteristics of new and emerging plaque psoriasis treatments such as efficacy, safety, and mechanism of action; strategies for fostering effective communication between patients and healthcare professionals; and choosing among the numerous treatment options for plaque psoriasis based on patient-, disease-, and agent-related characteristics.
This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs who manage patients with psoriasis. It will also be of benefit to primary care clinicians (internal medicine and family practice), including physicians, nurse practitioners, and PAs who manage patients with psoriasis.
Upon proper completion of this activity, participants should be better able to:
Review the pathophysiology of plaque psoriasis, particularly the roles of IL-12, IL-17, IL-23, TNF-alpha, PDE-4, and the JAK-STAT pathway
Explain current clinical trial data regarding new and emerging agents for moderate, and severe plaque psoriasis in order to engage patients in making treatment decisions
Select the most appropriate treatment for moderate, and severe plaque psoriasis based on important patient-, disease-, and drug-related characteristics
Conflict Of Interest Disclosure Policy
In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Gary Goldenberg, MD Assistant Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai Hospital New York, NY
Dr. Goldenberg discloses the following: Retained Consultant: AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Valeant Pharmaceuticals International, Inc. Speakers Bureau: AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation Honoraria: Valeant Pharmaceuticals International, Inc
Linda Stein Gold, MD Director of Clinical Research Department of Dermatology Henry Ford Hospital Detroit, MI
Dr. Stein Gold discloses the following: Grant/Research Support: Celgene Corporation; LEO Pharma Inc.; Pfizer Inc. Retained Consultant: Celgene Corporation; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Promius Pharma, LLC.; Taro Pharmaceutical Industries Ltd. Speakers Bureau: Celgene Corporation; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation; Taro Pharmaceutical Industries Ltd.
Accredited Provider Disclosures
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
University of Kentucky staff members have no financial relationships to disclose.
Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.
AMA PRA Category 1 Credit(s)TM
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Kentucky College of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
PA Continuing Education AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.50 Category 1 credits for completing this activity.
Nurse Practitioner Continuing Education The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the activity is provided solely by presenters who have been selected for the activity because of recognized expertise in their field.
Practice-based learning and improvement
The University of Kentucky is an Equal Opportunity University.
The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. Links are provided to other Internet sites solely for the convenience of users. Once you link to another site, you are subject to the site's terms and conditions of use including copyright and licensing restrictions.
This certified CME activity is designed using HTML5 audio and video.
For Desktops (Windows/Mac) Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface) iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher